Research progress on the treatment of advanced prostate cancer with Olaparib

被引：3

作者：

Su, Yi-Xin ^{[1
]}

Yu, Cheng-Feng ^{[1
]}

Xue, Peng ^{[1
]}

Li, Lin-Lu ^{[1
]}

Xiao, Kun-Min ^{[1
]}

Chu, Xue-Lei ^{[1
]}

Zhu, Shi-Jie ^{[1
]}

机构：

[1] China Acad Chinese Med Sci, Wangjing Hosp, Beijing, Peoples R China

来源：

NEOPLASMA | 2021年 / 68卷 / 06期

基金：

中国博士后科学基金;

关键词：

Olaparib; advanced prostate cancer; research progress; homologous recombination repair; synthetic lethality; DNA-REPAIR; MAMMARY-TUMORS; INHIBITOR; DAMAGE; RESISTANCE; MUTATIONS; COMBINATION; GENOMICS; THERAPY; BRCA2;

D O I：

10.4149/neo_2021_210627N856

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prostate cancer (PCa) is one of the most common malignancies in men worldwide, and metastatic castrate-resistant prostate cancer (mCRPC) has shown a poor prognosis. Although chemotherapy and androgen deprivation therapy (ADT) have improved clinical outcomes, the median survival (MS) of patients with mCRPC is still less than 2 years. With the development of poly adenosine diphosphate-ribose polymerase inhibitor (PARPi), the treatment strategy for patients with mCRPC has markedly evolved. Olaparib, a type of PARPi that can selectively induce synthetic lethality in cancer cells with homologous recombination (HR) deficiencies, was the first type of PARPi approved for treating patients with mCRPC harboring mutations in HR repair (HRR) genes. This review discusses and summarizes the latest progress on therapeutic mechanisms, monotherapy, combination therapy, and adverse events of Olaparib.

引用

页码：1132 / 1138

页数：7

共 56 条

[21] The current state of hormonal therapy for prostate cancer [J].

Hellerstedt, BA ;

Pienta, KJ .

CA-A CANCER JOURNAL FOR CLINICIANS, 2002, 52 (03) :154-179

[22] Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer [J].

Hussain, Maha ;

Mateo, Joaquin ;

Fizazi, Karim ;

Saad, Fred ;

Shore, Neal ;

Sandhu, Shahneen ;

Chi, Kim N. ;

Sartor, Oliver ;

Agarwal, Neeraj ;

Olmos, David ;

Thiery-Vuillemin, Antoine ;

Twardowski, Przemyslaw ;

Roubaud, Guilhem ;

Ozguroglu, Mustafa ;

Kang, Jinyu ;

Burgents, Joseph ;

Gresty, Christopher ;

Corcoran, Claire ;

Adelman, Carrie A. ;

de Bono, Johann .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (24) :2345-2357

[23] BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance [J].

Jaspers, Janneke E. ;

Sol, Wendy ;

Kersbergen, Ariena ;

Schlicker, Andreas ;

Guyader, Charlotte ;

Xu, Guotai ;

Wessels, Lodewyk ;

Borst, Piet ;

Jonkers, Jos ;

Rottenberg, Sven .

CANCER RESEARCH, 2015, 75 (04) :732-741

[24] Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors [J].

Jaspers, Janneke E. ;

Kersbergen, Ariena ;

Boon, Ute ;

Sol, Wendy ;

van Deemter, Liesbeth ;

Zander, Serge A. ;

Drost, Rinske ;

Wientjens, Ellen ;

Ji, Jiuping ;

Aly, Amal ;

Doroshow, James H. ;

Cranston, Aaron ;

Martin, Niall M. B. ;

Lau, Alan ;

O'Connor, Mark J. ;

Ganesan, Shridar ;

Borst, Piet ;

Jonkers, Jos ;

Rottenberg, Sven .

CANCER DISCOVERY, 2013, 3 (01) :68-81

[25] Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study [J].

Joshua, A. M. ;

Gurney, H. ;

Retz, M. ;

Tafreshi, A. ;

Fong, P. C. C. ;

Shore, N. D. ;

Romano, E. ;

Augustin, M. ;

Piulats, J. M. ;

Berry, W. R. ;

Kolinsky, M. P. ;

Sridhar, S. S. ;

Conter, H. J. ;

Todenhoefer, T. ;

Appleman, L. J. ;

Wu, H. ;

Schloss, C. ;

Poehlein, C. H. ;

de Bono, J. S. ;

Yu, E. Y. .

ANNALS OF ONCOLOGY, 2020, 31 :S1325-S1325

[26] Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations [J].

Karzai, Fatima ;

VanderWeele, David ;

Madan, Ravi A. ;

Owens, Helen ;

Cordes, Lisa M. ;

Hankin, Amy ;

Couvillon, Anna ;

Nichols, Erin ;

Bilusic, Marijo ;

Beshiri, Michael L. ;

Kelly, Kathleen ;

Krishnasamy, Venkatesh ;

Lee, Sunmin ;

Lee, Min-Jung ;

Yuno, Akira ;

Trepel, Jane B. ;

Merino, Maria J. ;

Dittamore, Ryan ;

Marte, Jennifer ;

Donahue, Renee N. ;

Schlom, Jeffrey ;

Killian, Keith J. ;

Meltzer, Paul S. ;

Steinberg, Seth M. ;

Gulley, James L. ;

Lee, Jung-Min ;

Dahut, William L. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[27] Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma [J].

Kondrashova, Olga ;

Nguyen, Minh ;

Shield-Artin, Kristy ;

Tinker, Anna V. ;

Teng, Nelson N. H. ;

Harrell, Maria I. ;

Kuiper, Michael J. ;

Ho, Gwo-Yaw ;

Barker, Holly ;

Jasin, Maria ;

Prakash, Rohit ;

Kass, Elizabeth M. ;

Sullivan, Meghan R. ;

Brunette, Gregory J. ;

Bernstein, Kara A. ;

Coleman, Robert L. ;

Floquet, Anne ;

Friedlander, Michael ;

Kichenadasse, Ganessan ;

O'Malley, David M. ;

Oza, Amit ;

Sun, James ;

Robillard, Liliane ;

Maloney, Lara ;

Bowtell, David ;

Giordano, Heidi ;

Wakefield, Matthew J. ;

Kaufmann, Scott H. ;

Simmons, Andrew D. ;

Harding, Thomas C. ;

Raponi, Mitch ;

McNeish, Iain A. ;

Swisher, Elizabeth M. ;

Lin, Kevin K. ;

Scott, Clare L. .

CANCER DISCOVERY, 2017, 7 (09) :984-998

[28] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial [J].

Ledermann, Jonathan ;

Harter, Philipp ;

Gourley, Charlie ;

Friedlander, Michael ;

Vergote, Ignace ;

Rustin, Gordon ;

Scott, Clare L. ;

Meier, Werner ;

Shapira-Frommer, Ronnie ;

Safra, Tamar ;

Matei, Daniela ;

Fielding, Anitra ;

Spencer, Stuart ;

Dougherty, Brian ;

Orr, Maria ;

Hodgson, Darren ;

Barrett, J. Carl ;

Matulonis, Ursula .

LANCET ONCOLOGY, 2014, 15 (08) :852-861

[29] PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies [J].

Lee, J-m. ;

Ledermann, J. A. ;

Kohn, E. C. .

ANNALS OF ONCOLOGY, 2014, 25 (01) :32-40

[30] EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression [J].

Lheureux, Stephanie ;

Oaknin, Ana ;

Garg, Swati ;

Bruce, Jeffrey P. ;

Madariaga, Ainhoa ;

Dhani, Neesha C. ;

Bowering, Valerie ;

White, Justin ;

Accardi, Sarah ;

Tan, Qian ;

Braunstein, Marsela ;

Karakasis, Katherine ;

Cirlan, Iulia ;

Pedersen, Stephanie ;

Li, Tiantiam ;

Farinas-Madrid, Lorena ;

Lee, Yeh Chen ;

Liu, Zhihui ;

Pugh, Trevor J. ;

Oza, Amit M. .

CLINICAL CANCER RESEARCH, 2020, 26 (16) :4206-4215

← 1 2 3 4 5 6 →